Search results for "Embolization"

showing 10 items of 156 documents

Selective Transarterial Chemoembolization of Advanced Hepatocellular Carcinomas: A Reasonable Palliative Option

2008

Abstract Background The purpose of this study was to provide information concerning the performance of selective transarterial chemoembolization (TACE) as a palliative treatment in patients with hepatocellular carcinoma (HCC), also in the case of multifocal lesions. Patients and methods We reviewed prospectively collected data on 43 patients with cirrhosis and HCC who underwent selective TACE as a palliative treatment. Patients were assigned to one of two groups: (1) those with one to three HCC lesions, and (2) those with four or more HCC lesions. Results One hundred and two TACE sessions were applied in 43 patients. There were 39 men and 4 women with a mean age of 65.5 ± 8.273 years. Alpha…

Malemedicine.medical_specialtyCarcinoma HepatocellularCirrhosismedicine.medical_treatmentGastroenterologyInternal medicinemedicineHumansIn patientEmbolizationChemoembolization TherapeuticAgedNeoplasm StagingRetrospective StudiesTransplantationAlpha fetoprotein levelsbusiness.industryLiver NeoplasmsPalliative CareAngiographyCancerMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryTransplantationHepatocellular carcinomaFemaleSurgeryalpha-FetoproteinsTomography X-Ray ComputedbusinessLiver cancerTransplantation Proceedings
researchProduct

Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients.

2012

Abstract Purpose The aim of our study was to assess the results and cost of a treatment strategy involving transarterial chemoembolisation with drug eluting beads (DEB-TACE) in patients with unresectable non-metastatic hepatocellular carcinoma (HCC). Patients and methods This study included all patients treated with DEB-TACE in our hospital between January 2009 and December 2010. All patients received DEB-TACE on demand and were evaluated after each session. Results Twenty-one patients received an average of 1.3 sessions. The median time to treatment discontinuation and median progression-free survival was 181 days and 295 days, respectively. Toxicity caused treatment discontinuation in thr…

Malemedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomaCostResultDrug Delivery SystemsTransarterial chemoembolisationOn demandmedicineHumansRadiology Nuclear Medicine and imagingIn patientChemoembolization TherapeuticAgedRetrospective StudiesAged 80 and overRadiological and Ultrasound TechnologyDrug eluting beadsbusiness.industryLiver NeoplasmsGeneral MedicineDirect costMiddle Agedmedicine.diseaseDrug eluting beadsMicrospheresSurgeryDiscontinuationTreatment OutcomeMedian timeHepatocellular carcinomaCosts and Cost AnalysisFemaleProspective payment systembusinessDiagnostic and interventional imaging
researchProduct

Editorial: IDASPHERE phase I trial for chemoembolisation for HCC - authors' reply: a necessary step for treatment optimisation and standardisation

2014

Malemedicine.medical_specialtyCarcinoma HepatocellularHepatologybusiness.industryLiver NeoplasmsGastroenterologyPhase (combat)medicineHumansFemalePharmacology (medical)Medical physicsChemoembolization TherapeuticIdarubicinbusinessAlimentary Pharmacology & Therapeutics
researchProduct

Chemoembolization for primary liver cancer

2002

Abstract Aims: For most patients with primary liver cancer surgical treatment is not feasible and prognosis without treatment is poor. We aimed to assess the morbidity and efficacy of transarterial chemoembolization (TACE) with lipiodol and mitomycin C in these patients in a prospective case-control study. Methods: From August 1996 to May 2000 22 patients with non-resectable hepatocellular carcinoma were treated with TACE. In case of radiological or tumour-marker response, treatment was repeated after 4–6 weeks, up to seven times per patient. Results: Morbidity was 23% and usually minor, no patient died within 30 days of treatment. A decrease in size of the reference tumour or constant tumo…

Malemedicine.medical_specialtyCarcinoma HepatocellularMitomycinmedicine.medical_treatmentGastroenterologyInternal medicinemedicineHumansProspective StudiesEmbolizationChemoembolization TherapeuticSurvival rateAgedAged 80 and overChemotherapyAntibiotics Antineoplasticbusiness.industryLiver NeoplasmsMitomycin CIodized OilGeneral MedicineMiddle Agedmedicine.diseaseSurgerySurvival RateOncologyCase-Control StudiesRadiological weaponHepatocellular carcinomaLipiodolFemaleSurgeryalpha-FetoproteinsComplicationbusinessmedicine.drugEuropean Journal of Surgical Oncology (EJSO)
researchProduct

Midterm follow-up after DC-BEAD™-TACE of Hepatocellular Carcinoma (HCC)

2012

Abstract Aim To determine local response, its predictors and survival and complication rates after DC-Bead™-TACE in patients with hepatocellular carcinoma (HCC). Materials and methods DC-Beads™ are non-resorbable, polyvinyl-alcoholic hydrophilic microspheres. They release high amounts of chemotherapeutics directly into the tumour. Delivery is sustained over time, tumour feeders are embolised. We used beads from 100–300 to 500–700 μm loaded with Doxorubicin (max. 150 mg/4 ml). Fifty patients (mean age: 68.5 ± 8.8 years) with HCC were analysed. DC-Bead™-TACE was performed once or repeated in two-month intervals. Imaging scans (CT or MRI) were done one-month following each procedure. To evalua…

Malemedicine.medical_specialtyCarcinoma HepatocellularPleural effusionAntineoplastic AgentsComorbidityGastroenterologyRisk FactorsGermanyInternal medicinePrevalencemedicineCarcinomaHumansRadiology Nuclear Medicine and imagingChemoembolization TherapeuticSurvival rateSurvival analysisAgedUltrasonographybusiness.industryLiver NeoplasmsGeneral Medicinemedicine.diseaseSurvival AnalysisSurgerySurvival RateTreatment OutcomeDoxorubicinDelayed-Action PreparationsHepatocellular carcinomaFemaleLiver functionbusinessProgressive diseaseFollow-Up StudiesLiver abscessEuropean Journal of Radiology
researchProduct

Liver Transplantation for Hepatocellular Carcinoma After Yttrium Therapy: A Case Report

2008

Yttrium-90 microspheres constitute one of the most recent treatment options for hepatocellular carcinoma (HCC) in the setting of cirrhosis. As such, their spectrum of indication is not yet fully established. Herein, we have reported the case of a patient with HCC beyond the listing criteria for liver transplantation (OLT) who was treated preoperatively with selective transarterial chemoembolization and yttrium-90 microspheres. He was subsequently transplanted with a liver from an 81-year-old donor allocated through Eurotransplant as a "rescue offer." The posttransplant course was uneventful. Pathologic examination revealed a multifocal, well-differentiated pT2 tumor with no vascular invasio…

Malemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosismedicine.medical_treatmentLiver transplantationMicrospheremedicineHumansYttrium RadioisotopesChemoembolization TherapeuticAged 80 and overTransplantationbusiness.industryLiver NeoplasmsCancerTreatment optionsMiddle Agedmedicine.diseaseCombined Modality TherapyLiver TransplantationTumor recurrenceSurgeryTreatment Outcomesurgical procedures operativeHepatocellular carcinomaSurgerybusinessLiver cancerTransplantation Proceedings
researchProduct

Organ recipients suffering from undifferentiated neuroendocrine small-cell carcinoma of donor origin: a case report.

2009

Abstract Background Transmission of donor-derived cancer by organ transplantation is rare, but the risk has been increasing due to the aging donor pool. Undifferentiated neuroendocrine small-cell carcinoma is an agressive tumor with the tendency to spread. Herein we have demonstrated different approaches to treat organ recipients with transmitted tumors. Methods and Results Grafts were retrieved from a decreased donor without any history of previous diseases. Autopsy was not performed after donation. The recipient of the liver graft presented with suspected nodules on routine abdominal ultrasound. After computed tomography (CT) scan, biopsy confirmed the diagnosis of a small-cell carcinoma.…

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentAutopsyAntineoplastic AgentsSmall-cell carcinomaNephrectomyOrgan transplantationCarboplatinalpha 1-Antitrypsin DeficiencyBiopsymedicineCarcinomaHumansCarcinoma Small CellNeoplasm MetastasisEtoposideTransplantationChemotherapymedicine.diagnostic_testbusiness.industryLiver NeoplasmsCancerMiddle Agedmedicine.diseaseDNA FingerprintingEmbolization TherapeuticKidney TransplantationTissue DonorsSurgeryLiver TransplantationTransplantationHeart TransplantationSurgerybusinessImmunosuppressive AgentsTransplantation proceedings
researchProduct

Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma.

2006

Criteria to select patients with hepatocellular carcinoma (HCC) for liver transplantation (LT) are based on tumor size and number of nodules rather than on tumor biology. The present study was undertaken to assess the role of transarterial chemoembolization (TACE) in selecting patients with tumors suitable for LT. Ninety-six consecutive patients with HCC were treated by repeatedly performed TACE, 62 of them exceeding the Milan criteria. Patients meeting the Milan criteria were immediately listed, and patients beyond the listing criteria were listed upon downstaging of the tumor following successful TACE. Fifty patients were finally transplanted. Of these 50 patients, 34 exceeded the Milan c…

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentKaplan-Meier EstimateLiver transplantationMilan criteriaGastroenterologyRecurrenceInternal medicineCarcinomaMedicineHumansChemoembolization TherapeuticSurvival rateRetrospective StudiesTransplantationHepatologybusiness.industryPatient SelectionLiver NeoplasmsRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryLiver TransplantationTransplantationSurvival RateTreatment OutcomeHepatocellular carcinomaRelative riskDisease ProgressionSurgeryFemalebusinessLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
researchProduct

Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials

1997

Summary Background Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death. Many treatments have been proposed but considerable uncertainty still remains about their effectiveness. In this review we evaluated the quality, clinical coherence, consistency and results of Randomized Controlled Trials (RCT) of non-surgical treatments for HCC. Methods Thirty-seven RCTs examining the effect of different treatments were retrieved using MEDLINE (November 1978 to December 1995) and a review of reference lists. Selected aspects of the quality of design, conduct and reporting were examined. The odds ratio for the probability of surviving up to one year was calculated according to the …

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentlaw.inventionRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAdjuvant therapyHumansEmbolizationRandomized Controlled Trials as Topicbusiness.industryArterial EmbolizationLiver NeoplasmsHematologyOdds ratioEmbolization TherapeuticChemotherapy regimenSurgeryClinical trialClinical Trials Phase III as TopicOncologyMeta-analysisImmunotherapybusinessAnnals of Oncology
researchProduct

Spontaneous Symptomatic Common Carotid Artery Pseudoaneurysm: Case Report and Literature Review

2015

Spontaneous common carotid artery pseudoaneurysm (CCAP) is rare but potentially lethal disease. A 78-year-old man presented with pain in correspondence of right neck side and slight right eye ptosis. No previous surgery, trauma, or venous catheterizations in the neck region were reported. The computed tomographic angiography (CTA) showed a 4-cm saccular CCAP. The patient was managed emergently with surgical CCAP excision. At 6-month follow-up, the patient is neck pain-free with complete ptosis regression, and the CTA shows no pathologic findings. The literature review reported 7 cases of pseudoaneurysm of carotid district. All these cases were managed by surgical approach, and in 1 case, an…

Malemedicine.medical_specialtyCarotid Artery CommonEmbolization procedureSettore MED/22 - Chirurgia VascolarePseudoaneurysmAneurysmPtosismedicine.arterymedicineHumanscardiovascular diseasesCommon carotid arteryAgedSurgical repairmedicine.diagnostic_testbusiness.industryEndovascular ProceduresAngiographyGeneral Medicinemedicine.diseaseSurgeryComputed tomographic angiographyAngiographycardiovascular systemSurgeryRadiologymedicine.symptomTomography X-Ray ComputedCardiology and Cardiovascular MedicinebusinessAneurysm FalseAnnals of Vascular Surgery
researchProduct